NCT01726933View on ClinicalTrials.gov

LAS41008 in Moderate to Severe Chronic Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

839

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

October 31, 2014

Study Completion Date

November 30, 2015

Conditions
Plaque Psoriasis
Interventions
DRUG

LAS41008

gastric resistant tablet, weekly up-titration up to maximal tolerated dosage

DRUG

LASW1835

gastric resistant tablet, weekly up-titration up to maximal tolerated dosage

DRUG

Placebo

gastric resistant tablet, weekly up-titration up to maximal tolerated dosage

Trial Locations (4)

Unknown

Investigatives site names will not be disclosed to avoid competitive information. Specify at least one site as follows: Almirall Investigative Site, Various

Investigatives site names will not be disclosed to avoid competitive information. Specify at least one site as follows: Almirall Investigative Site, Various

Investigatives site names will not be disclosed to avoid competitive information. Specify at least one site as follows: Almirall Investigative Site, Various

Investigatives site names will not be disclosed to avoid competitive information. Specify at least one site as follows:Almirall Investigative Site #, Various

Sponsors

Lead Sponsor

Almirall, S.A.
All Listed Sponsors
collaborator

Almirall Hermal GmbH

INDUSTRY

collaborator

Harrison Clinical Research

INDUSTRY

lead

Almirall, S.A.

INDUSTRY